Cortice Biosciences announced today results from placebo-controlled, double-blinded Phase 1 studies evaluating TPI 287, a brain penetrable microtubule stabilizing agent, for the treatment of Alzheimer’s disease, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
A new study identifies a possible therapeutic target for memory loss in some neurodegenerative diseases, including Alzheimer's.
Researchers identify a therapeutic target for clearing toxic proteins in Alzheimer's and other neurodegenerative diseases.
According to a new study, a drug previously prescribed for rheumatoid arthritis have been found to successfully reverse tau related symptoms in animal models of dementia.
A new study reports appoptosin initiates a path that leads to tau accumulation in neurodegenerative disorders.
Researchers discover neuronal activity can stimulate tau release from healthy neurons in the absence of cell death. The study shows treatment of neurons with known biological signaling molecules increases the release of tau into the culture medium.